[Skip to Navigation]
April 1988

Single Photon Emission Computed Tomography in Alzheimer's Disease: Abnormal Iofetamine I 123 Uptake Reflects Dementia Severity

Author Affiliations

From the Department of Neurology, Massachusetts General Hospital and Harvard Medical School (Drs Johnson and Growdon), the Department of Radiology, Brigham and Women's Hospital and Harvard Medical School (Drs Holman, Mueller, and Nagel and Mr English), Boston; and the Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge (Dr Rosen).

Arch Neurol. 1988;45(4):392-396. doi:10.1001/archneur.1988.00520280038013

• To determine whether abnormalities in regional cerebral functional activity estimated by iofetamine hydrochloride I 123 and single photon emission computed tomography can be detected in mild or moderate as well as severe cases of Alzheimer's disease (AD), we performed iofetamine I 123-single photon emission computed tomography in 37 patients with probable AD (nine patients with mild, 18 patients with moderate, and ten patients with severe dementia) and nine age-matched control subjects. lofetamine I 123 uptake was measured in right and left frontal, temporal, parietal, and occipital cortices. Mean (right and left) iofetamine I 123 activity was lowest in the parietal region of patients with AD and was significantly reduced in the other three regions compared with control subjects. Only in the parietal region was lower relative iofetamine I 123 activity associated with an impaired level of patient function and with cognitive deficit.

Add or change institution